DOCSLIB.ORG

Central Nervous System Depressants

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Central Nervous System Depressants CENTRAL NERVOUS SYSTEM DEPRESSANTS GENERAL The central nervous system depressants are drugs sulfonmethanes (Table X) comprise drugs that that relieve anxiety (sedatives) or induce sleep cause, in high dose, sedation, stupor, coma, impaired (hypnotics). Chemical groups of the monoureides cognition, loss of behavioural controls and ataxia. (Table II), sulfonmethanes (Table X), and the In addition, there is experimental or experiential miscellaneous agents (Table XI) comprise drugs evidence that at least one member of each of these which have low or no dependence liability but which subgroups causes dependence of the barbiturate- have high central nervous system and other organ alcohol type, manifested by nervousness, agitation, toxicity. These drugs are largely obsolete and insomnia, confusion, convulsions and delirium production is generally low. The bromides have following abrupt discontinuation after long-conti- similar dangers. nued high dosage. A small number of individual The chemical groups of the barbiturates (Table I), drugs have also been shown to substitute for barbital chloral and derivatives (Table III), the tertiary in dogs or monkeys dependent on those substances, acetylenic alcohols (Table IV), the carbamic acid that is, have been shown to have physical dependence esters of monohydroxy alcohols (Table V), the capacity of the barbiturate type, and in such in- carbamic acid esters of glycols (Table VI), the stances cross-tolerance was clearly demonstrated. piperidinediones (Table VII), the quinazolinones The cyclic ether, paraldehyde, has similar character- (Table VIII), the benzodiazepines (Table IX) and the istics. DIUREIDES (BARBITURATES) The fact that the barbiturates (Table I) are drugs of central nervous system depressants. Kalinowsky's of dependence is now so well accepted that it is idea was expanded to include the group of drugs difficult to remember how long this fact was denied listed under substances that cause dependence of the and how long it took to gain general acceptance of barbiturate-alcohol type. 87 barbiturate-type dependence. The first cases of The characteristics of dependence of the barbitu- dependence were described as long ago as 1914 116 rate-alcohol type include: and 1915.125 The general clinical aspects of the (1) strong psychic dependence; intoxication and of the withdrawal manifestations (2) intoxication manifested by sedation, sleep, were reported in 1928 119 and further detailed in a coma, stupor, impaired cognition and judgement, monograph 120 in 1934. Dependence with withdraw- and ataxia; al convulsions in dogs was demonstrated in 1939 128 and confirmed later.84, 82 Numerous cases of with- (3) development of tolerance which is partly bio- drawal convulsions and delirium were reported chemical due to induction of increased amounts of around the world from 1914 to 1950, but the concept drug-metabolizing enzymes in the liver and to that the barbiturates caused physical dependence " cellular" tolerance within the central nervous continued to be denied until the experimental de- system (tolerance to this type of drug, in contrast to monstration of the condition in controlled experi- opiates, has a definite limit); ments in man 78, 93, 95, 96, 103, 104, 106, 129 in 1950 and (4) partial crossed tolerance between members of subsequent years. the group; Kalinowsky I" was the first to recognize that (5) a dangerous type of physical dependence convulsions on withdrawal of barbiturates, alcohol manifested by anxiety, insomnia, weakness, tremors, and other drugs represented a general type of EEG abnormalities, convulsions and delirium on reaction common to several different chemical types withdrawal. -10 - _ 0 ,W . WV 9 C co _-'_ CZ *. < C C*C-oC- mgo rc V. aD o -ce >>0 w_V" O r__V;o_v co C nWX 0 CL C E OUC C C zD~~~~~~~~~~~~~~~~~~~~~~~~ 07 | t U ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~D01 C E O *- to cis !t CAcsO E ; a CD a E c SO=0@. nm , s =0 11 N~~~~~~~~~~~~~~~~~~~~~~~~~~o E.. | - _ns .=Z _>< 0 0 .2 Zs f 0 O W101= @eE OEE _ E LeZtoC C CD 0n_ OZw.S Co ca C, (n :3 0 cn noQ .a cn 0E0 co Z Q D X a Z ._ (D_3 cr i D Z 0as iL ,E =o 0 C~ .o mW 0 \ / 0 , co o°u, 1 U1 0 co o0 a L) zm Z CLo on '5:cIO z d-z1 fM\/ 0 " \11/ N- ...- . 7 __ o~~~~~~4 C-D j1 .oI0 7* 0 =M as o ._X <n u3(?'0 jz E c U ,U w- en 0 0.QX W=sn 11 - 0 ^0 a) co^0 6-ico- 0'r- C4 a - -X0 CoOON-.- -- co CGO C- c- m CO- a- co: COra ia, CO 0 cm- atQC-- a)It _O_ _ cm - - U) PLat -____ l-OD_ 0 CCO r- - a) - - - - o V,CO6OaC 4-0 No ) 6_- r. 0 cq IV N4 C c- 4qc- N~ CN I- r-f_C __-v C.-CO- v w I- 0~~~~~a CL ~~ ~ ~ 000 0 W U 42 U 0 U cn CO C 4 .2 0 4) m 0 W C0 0 co )D- U) 0 MaO U) U a)U a -I C :1 C O z4 o : ; W Oc4oOD) vO c. Q;o-oC)QO Dc.-o.D C-E~~~ ~~oa.. -Dua 0(t! CL c. 2cUQ E02 OCe. C)S.2aC (0 U 0L 0c. -0 C 3t 0 E~~~~~~~~~~~~0 0) 0 0~~~~~~a a) 0C I- UtCD .0 . IL CL 0 m ~ ~~~~0 Ut 0 *0 a. U ~~~~~~~~~~E 0 0~~~~~~~~~~~~~...0 00~~~~~~~~~~~~0 :-O CO no.2 C~~~~~~~~~~~ ~~~~~~ 0~00 LJU) o.2Z.U) c ~~~~~~-...O. ): Jq2.wz.3 OUOW.0oz U) z - U) ta .0E U) .0 O W a) w 'c .0 _ X(D ='q Z=l 0. .0: 00COE- 00X z E0~cO co <e091n50u 0Q 0.alo co C O a)co 0 46< n en c 0c c6o w enI- a)L-co U) 2 U) 10 n U) e-0 zm co )_ co 0 U % CD .2 . 2 co Iii E x u z r r U co c >, .0 2: -J _a .0.a _* q .0n c_ U . m m .00 '0 ,,1C. o = m o i- 0) .s o > 0 m 0 H* co <>IOx: E a - N O z m e 0_N 3%.2 i MO O =z=t O i2 c cr W tW.. 0 .0 6 Z Cn L,; -Z z I 0 .0 c-i ui U U 2OQc r- L,; 0 Q co urt 0 U) - 12 .0 .0 - - U) 0 -a r a N c- U - u v- r- "- 05(0.l C r- C- rze- :Vi - co 0 r: C- r-)0)0a,:,0)_ _) 0 - - - CS) - -c CO - a) (0 r-0 - - - SD __C>C a) U- Ct C- rO .u,_ 0 L0 CO0..- CI Cq 0) 0 CS) 0) _6 c- O.-..- Uq00 _-- a).-*U tm> ) Gm:<0 ..C *0o 0 lo [o'c) 0 0I C 00 0 0 0 0 Q- 0 U U 0' s0 a) ,t ) o -oO0. --n o *-ln 0 o - I C i --0-C M E...a) c . Za) " @ c X ZD = * C AS C 4> C CaD° C CU)a)Z=CZ)...)a)) .)(a)aaa.) -D C za 5~Za ).Z)aa)C-) aC )Q 0...)a 0 oC C coC .l'o0C 3c . o CoO00 (D0n +-0M. o(ODE 0CCO.o0L:C0CCO.o+- C o U U 0O -. C ._2 Co =CC = U 0. U q5r- E I._ 0 0.>.- , - U.-.; a 0 0._ qs o ° co)a E co 0 C C6 A-, - a C9 -0 0l. Om 0l. > ClC1; 0 a) C FL Ic"J t/>U)I <.E DZ U) I z cJ I a..l *0 0 c a) a1) a) _CC) 0 ao a .0 -0 .0:a) CL aX O 0. 0 0 a.0 2_ 20 L- v0I0. z Z~.- 0. a. a) U .0 .0 0 ED Q C co D | ~ ~ ~~~~EE .0 .~DtoD|~ ~~~0.0 a. 0 0 0 0 0 0 a1) l- 0, Q0 o L- L-0O.- 0. 0.0a) a. Z.C Z a.,a. a C C 0 0 a) .0 .0 .0 .0 0 0 0 0 0 0 0 I.. ~~0 -.- 0 ..-% -L a. Z.rE Z.rE a. 0. 0. 0 ao 0co m - *-2 a)- '0 00O 0 o Ca-=C0.0 n a)W-. CZ C 0 0 na co 0 a)c Cl) In c ~~ ~~~~~ES zE~~0 0UU 0co z 4 U) a) ia C') m E 0 w Cza) 0 a .- E L. C. -0 0. 0 C9 o zccj a ) w z 0..- 0 Qa a zo zomQ co co -0 CD I- a) uc C0 C.- .0 .G- 0 .0 L- Uf) m a) .C.Z .20 U)w 0 E -> > 0 0 0 C .2 .2 co) .0 co .04 :0.1 _ ' 0. :>. H 5 I- ._ J 2 ~c 0 O cozoG a) z co =m a co C E _ _ s n .0 -J 0 ._)~ 4 coC Co a)co IQ II. ._ I- Co cJ C z ,*. : 4 w 0oE 'X 0: !: I0 rO- re re U :.. 2.2 C. Q .0 w 0 0-to W. -j z 0 m _c CM' co U E,o,* U 9) .5s I- U, U. Iu - 13 CO 0 0 CO XCo a 0 RNF ". c r- - 0 r- a °- co 0)O V_ V_ 0: r-CO - C- QJ -O - or- I __ --O-eR-ara_ 0 Q - 0o -V-- oQ COO co - - 1- f r v- - o U) C i 0 0 C- 0-.0 sC a 0 0 0 0 0 0 ~~~~ 0 ~~~~0 ~~~~ C U C)~~~0 Ul * 0 0 0 0 .-~~~~~~~o0 S 4 Ul .
Load more

Recommended publications
  • Sectionpm E] Analytical Кгейг“' Control Radiopharmaceuticals
    section P m e ] Analytical кгейг“' Control i - ¡ Q f Radiopharmaceuticals Proceedings of a Panel Vienna, • ° 7-11 July 1969 INTERNATIONAL ATOMIC ENERGY AGENCY, VIENNA, 1970 ANALYTICAL CONTROL OF RADIOPHARMACEUTICALS The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GREECE .NORWAY ALBANIA GUATEMALA PAKISTAN ALGERIA HAITI PANAMA ARGENTINA HOLY SEE PÂRAGUAY AUSTRALIA HUNGARY PERU AUSTRIA ICELAND PHILIPPINES BELGIUM INDIA POLAND BOLIVIA INDONESIA PORTUGAL BRAZIL IRAN ROMANIA BULGARIA IRAQ' SAUDI ARABIA BURMA IRELAND SENEGAL BYELORUSSIAN SOVIET ISRAEL SIERRA LEONE SOCIALIST REPUBLIC ITALY SINGAPORE CAMBODIA IVORY COAST SOUTH AFRICA CAMEROON JAMAICA SPAIN CANADA JAPAN SUDAN CEYLON JORDAN SWEDEN CHILE KENYA SWITZERLAND CHINA KOREA, REPUBLIC OF SYRIAN ARAB REPUBLIC COLOMBIA KUWAIT THAILAND CONGO, DEMOCRATIC LEBANON TUNISIA REPUBLIC OF LIBERIA TURKEY COSTA RICA LIBYAN ARAB REPUBliC UGANDA CUBA LIECHTENSTEIN UKRAINIAN'SOVIET SOCIALIST CYPRUS LUXEMBOURG REPUBLIC CZECHOSLOVAK SOCIALIST MADAGASCAR UNION OF SOVIET SOCIALIST REPUBLIC MALAYSIA REPUBLICS DENMARK MALI UNITED ARAB REPUBLIC DOMINICAN REPUBLIC MEXICO UNITED KINGDOM OF GREAT ECUADOR MONACO BRITAIN AND NORTHERN EL SALVADOR MOROCCO IRELAND ETHIOPIA NETHERLANDS UNITED STATES OF AMERICA FINLAND NEW ZEALAND URUGUAY FRANCE NICARAGUA VENEZUELA GABON NIGER VIET-NAM GERMANY, FEDERAL REPUBLIC OF NIGERIA YUGOSLAVIA GHANA *• ZAMBIA The Agency’s Statute was approved on 23 October 1956 by the Conference on the Statute of the IAEA held at United Nations Headquarters,
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0197411A1 Gao Et Al
    US 2004O197411A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0197411A1 Gao et al. (43) Pub. Date: Oct. 7, 2004 (54) ACCEPTABLY NON-HYGROSCOPIC Related U.S. Application Data FORMULATION INTERMEDIATE COMPRISINGA HYGROSCOPIC DRUG (60) Provisional application No. 60/435,147, filed on Dec. 19, 2002. Provisional application No. 60/435,022, (76) Inventors: Danchen Gao, Chicago, IL (US); Ann filed on Dec. 19, 2002. Provisional application No. M. Czyzewski, Grayslake, IL (US) 60/435,422, filed on Dec. 19, 2002. Correspondence Address: Publication Classification PHARMACIA CORPORATION 7 GLOBAL PATENT DEPARTMENT 8. s - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Ales POST OFFICE BOX 1027 Oa - 1 - O - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ST. LOUIS, MO 63006 (US) (57) ABSTRACT A Solid particulate composition is provided comprising a (21) Appl. No.: 10/741,530 hygroscopic and/or deliqueScent drug and at least one non hygroscopic polymer. The drug and the at least one polymer are in intimate association and the composition is acceptably (22) Filed: Dec. 18, 2003 non-hygroscopic. Patent Application Publication Oct. 7, 2004 Sheet 1 of 3 US 2004/0197411A1 FIG. 1 40 Mass Increase (%) 20 -- Compound 1 10 RH (%) Mass Increase (%) O 2O 40 60 80 1 OO 120 140 Time (h) Patent Application Publication Oct. 7, 2004 Sheet 2 of 3 US 2004/0197411A1 MaSS increase (%) O 2O 40 60 80 1 OO 12O 140 Mass Increase (%) O 1 OO 2OO 3OO 400 5 OO Patent Application Publication Oct. 7, 2004 Sheet 3 of 3 US 2004/0197411A1 F.G. 5 Mass Increase (%) O 2O 40 6O 8O 1 OO 12O 140 160 US 2004/O1974 11 A1 Oct.
    [Show full text]
  • Determination of Barbiturates and 11-Nor-9-Carboxy-Δ9-THC in Urine
    Determination of Barbiturates and 11-Nor-9-carboxy- 9-THC in Urine using Automated Disposable Pipette Extraction (DPX) and LC/MS/MS Fred D. Foster, Oscar G. Cabrices, John R. Stuff, Edward A. Pfannkoch GERSTEL, Inc., 701 Digital Dr. Suite J, Linthicum, MD 21090, USA William E. Brewer Department of Chemistry and Biochemistry, University of South Carolina, 631 Sumter St. Columbia, SC 29208, USA KEYWORDS DPX, LC/MS/MS, Sample Preparation, High Throughput Lab Automation ABSTRACT This work demonstrates the use of disposable pipette extraction (DPX) as a fast and automated sample preparation technique for the determination of barbiturates and 11-nor-9- carboxy- 9-THC (COOH-THC) in urine. Using a GERSTEL MultiPurpose Sampler (MPS) with DPX option coupled to an Agilent 6460 LC-MS/MS instrument, 8 barbiturates and COOH-THC were extracted and their concentrations determined. The resulting average cycle time of 7 min/ sample, including just-in-time sample preparation, enabled high throughput screening. Validation results show that the automated DPX-LC/ AppNote 1/2013 MS/MS screening method provides adequate sensitivity for all analytes and corresponding internal standards that were monitored. Lower limits of quantitation (LLOQ) were found to be 100 ng/mL for the barbiturates and 10 ng/mL for COOH-THC and % CVs were below 10 % in most cases. INTRODUCTION The continuously growing quantity of pain management sample extract for injection [1-2]. The extraction of the drugs used has increased the demand from toxicology Barbiturates and COOH-THC is based on the DPX-RP- laboratories for more reliable solutions to monitor S extraction method described in an earlier Application compliance in connection with substance abuse and/or Note detailing monitoring of 49 Pain Management diversion.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Col.V.MISSION of the EUROPEAN COMMUNITIES
    COl.V.MISSION OF THE EUROPEAN COMMUNITIES SEC(90) 1985 final· Brussels, 29 October 1990 Proposa I for a COUNCIL DIRECTIVE on the approximation of the laws of the Member States relat.ing to cosmetic products -2- EXPLANATORY UEUORANDUM 1. In the context of a people's Europe, the Commission attaches great Importance to simplifying and clarifying Community law so as to make It clearer and more accessible to the ordinary citizen, thus giving hIm new opportunItIes and the chance to make use of the spec if i c rights It gives him. This aim cannot be achieved so long as numerous provisions that have been amended several times, often QUite substantially, remain scattered, so that they must be sought partly In the original Instrument and partly In later amending ones. Considerable research work, comparing many different Instruments, Is thus needed to Identify the current rules. For this reason a consot tdatton of rules that have freQuently been amended Is essential If Community law Is to be clear and transparent. 2. In Its resolution of 26 November 1974 concerning consolidation of Its acts (1), the Council recommended that those of Its acts which have been amended several times be assembled Into a single text. It stressed that, In the Interests of legal certainty, a genuine legislative consolidation, Involving the repeal of earlier acts, should wherever possible be effected (as Is being done In this case). it conseQuently Invited the Commission to let it have proposals for consol !dation and undertook ·to examine them "as Quickly as possible, whltout bringing Into QUestion, during that consol ldatlon, the substantive solutions contained In the consol !dated texts".
    [Show full text]
  • Oral Fluid Drug Test Package Insert
    Marijuana (THC) 11-nor-Δ9-THC-9 COOH 4 MTD: Methadone is a synthetic analgesic drug originally used for the Oral Fluid Drug Test treatment of narcotic addiction. In addition to use as a narcotic agonist, methadone is being used more frequently as a pain management agent. The Marijuana (THC) Δ9-THC 50 Package Insert psychological effects induced by using methadone are analgesia, sedation, and respiratory depression. Based on the saliva/plasma ratio calculated over Package insert for testing of the following drugs: > 0.02 % Alcohol (ALC) Alcohol salivary pH ranges of 6.4-7.6 for therapeutic or recreational doses of Amphetamine,Cocaine,Marijuana,Methamphetamine,Opiate,Methadone, B.A.C methadone, a cut-off <50 ng/mL is suggested. Due to this recommendation, Phencyclidine,Oxycodone,Benzodiazepine,Buprenorphine,Barbiturates, the cut-off level of the methadone test was calibrated to 30 ng/mL. Cotinine,EDDP,MDMA,6-MAM,Propoxyphene ,Fentanyl,ETG and Alcohol Tramadol(TRA) 50 Tramadol PCP: Phencyclidine is a hallucinogen and, can be detected in oral fluid as a INTENDED USE & SUMMARY result of the exchange of the drug between the circulatory system and the oral cavity.5 Fentanyl(FEN) 10 The Oral Fluid Drug And Alcohol Test is intended for screening for the Norfentanyl presence of drugs and alcohol and their metabolites in oral fluid. For professional in vitro diagnostic use only. OXY: Oxycodone is a semi-synthetic opioid with a structural similarity to Ethyl codeine. The drug is manufactured by modifying thebaine, an alkaloid found in 150 The Oral Fluid Pipette Test is a lateral flow chromatographic immunoassay for Glucuronide(ETG) the opium poppy.
    [Show full text]
  • Review Memorandum
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k062165 B. Purpose for Submission: New device C. Measurand: Barbiturates D. Type of Test: Qualitative and semi-quantitative enzyme immunoassay E. Applicant: Ortho-Clinical Diagnostics, Inc. F. Proprietary and Established Names: VITROS Chemistry Products BARB Reagent VITROS Chemistry Products Calibrator 26 VITROS Chemistry Products FS Calibrator 1 VITROS Chemistry Products DAT Performance Verifiers I, II, III, IV and V G. Regulatory Information: 1. Regulation section: 21 CFR 862.3150, Barbiturates test system 21 CFR 862.3200, Clinical Toxicology Calibrator 21 CFR 862.3180, Clinical Toxicology Control 2. Classification: Class II, (reagent, calibrator) Class I, reserved (control) 3. Product code: DIS, DLJ and DIF 4. Panel: Toxicology (91) 1 H. Intended Use: 1. Intended use(s): See Indications for use. 2. Indication(s) for use: VITROS Chemistry Products BARB Reagent: For in vitro diagnostic use only. VITROS Chemistry Products BARB Reagent is used on VITROS 5,1 FS Chemistry Systems for the semi- quantitative or qualitative determination of barbiturates (BARB) in human urine using a cutoff of 200 ng/mL or 300 ng/mL. Measurements obtained with the VITROS BARB method are used in the diagnosis and treatment of barbiturates use or overdose. The VITROS Chemistry Products BARB assay is intended for use by professional laboratory personnel. It provides only a preliminary test result. A more specific alternative chemical method must be used to confirm a result with this assay. Gas Chromatograpy/Mass Spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug-of-abuse test result, particularly when evaluating a preliminary positive result.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Intravenous Anesthetics  a Drug That Induces Reversible Anesthesia  the State of Loss of Sensations, Or Awareness
    DR.MED. ABDELKARIM ALOWEIDI AL-ABBADI ASSOCIATE PROF. FACULTY OF MEDICINE THE UNIVERSITY OF JORDAN Goals of General Anesthesia Hypnosis (unconsciousness) Amnesia Analgesia Immobility/decreased muscle tone (relaxation of skeletal muscle) Reduction of certain autonomic reflexes (gag reflex, tachycardia, vasoconstriction) Intravenous Anesthetics A drug that induces reversible anesthesia The state of loss of sensations, or awareness. Either stimulates an inhibitory neuron, or inhibits an excitatory neuron. Organs are divided according to blood perfusion: High- perfusion organs (vessel-rich); brain takes up disproportionately large amount of drug compared to less perfused areas (muscles, fat, and vessel-poor groups). After IV injection, vessel-rich group takes most of the available drug Drugs bound to plasma proteins are unavailable for uptake by an organ After highly perfused organs are saturated during initial distribution, the greater mass of the less perfused organs continue to take up drug from the bloodstream. As plasma concentration falls, some drug leaves the highly perfused organs to maintain equilibrium. This redistribution from the vessel-rich group is responsible for termination of effect of many anesthetic drugs. Compartment Model Inhibitory channels : GABA-A channels ( the main inhibitory receptor). Glycine channels. Excitatory channels : Neuronal nicotic. NMDA. Rapid onset (mainly unionized at physiological pH) High lipid solubility Rapid recovery, no accumulation during prolonged infusion Analgesic
    [Show full text]
  • Revista Medica Hondurena
    Revista MEDICA HONDURENA (2* Época) ÓRGANO DEL COLEGIO MEDICO DE HONDURAS FUNDADA EN 1930 CONSEJO EDITORIAL RICARDO VILLELA VIDAL Director RIGOBERTO ARRIAGA CHINCHILLA Secretario Redactores: HENA CARDONA DE HERRERA ARMANDO PAVÓN AGUILERA CARLOS H. RIVERA MEDINA JORGE TULIO GALEAS A. Administración: "COLEGIO MEDICO DE HONDURAS" Oficina' "Colegio Médico de Honduras", Tegucigalpa, D. C. Tel. 22-5466 Apartado Postal N9 810 SE SOLICITA CANJE Imprenta LÓPEZ Y CÍA. EDITORIAL DR. RICARDO VILLELA-VIDAL Con la publicación de este número ha terminado la misión a nosotros enco- mendada, es decir, darle vida por un año al órgano oficial de publicidad del Colegio Médico de Honduras: La REVISTA MEDICA HONDURENA. Seguros de haber cumplido con nuestro deber, dejamos en manos de los nombrados para sucedemos nuestra querida Revista. Y decimos nuestra porque ya forman parte de nuestra existencia el trabajo, el recuerdo y nuestra voluntad convertida en páginas escritas que llegaron —seguramente— como mensajeras del pensamiento médico hondureño hasta nuestros colegas paisanos, y más allá de las fronteras hondureñas. Nuestro trabajo sólo fue posible siguiendo la ruta trazada por quienes, en años anteriores, dieron vida e importancia (con esfuerzo y sacrificio) a tas1 páginas de la REVISTA MEDICA HONDURENA. Es indudable que en cada año por venir, con mejor estilo, con más trabajo y mayor buena voluntad, la Revista Médica Hondureña irá adquiriendo belleza y más prestigio. Es que nuevos valores médicos llegan año con año para surtir sus páginas con el producto de sus estudios e investigaciones en el campo interminable de las ciencias médicas. Las páginas que llevan y traen los nuevos conocimientos médicos deben ser las primeras que se abran cada día ante los ojos de los médicos de aquí y de allá, porque no podemos avanzar sin estudiar lo nuevo, sin recordar lo histórico y sin esperar cada día la llegada de los adelantos científicos.
    [Show full text]